INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $214,619 | +8.9% | 11,576 | -18.1% | 0.00% | 0.0% |
Q3 2022 | $197,000 | +1.0% | 14,126 | 0.0% | 0.00% | – |
Q2 2022 | $195,000 | -35.9% | 14,126 | -24.5% | 0.00% | -100.0% |
Q1 2022 | $304,000 | -0.3% | 18,706 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $305,000 | +9.7% | 18,706 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $278,000 | -25.7% | 18,706 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $374,000 | +30.8% | 18,706 | +51.0% | 0.00% | 0.0% |
Q1 2021 | $286,000 | -12.0% | 12,388 | -6.0% | 0.00% | 0.0% |
Q4 2020 | $325,000 | -43.6% | 13,178 | -5.2% | 0.00% | 0.0% |
Q3 2020 | $576,000 | -8.9% | 13,898 | +5.3% | 0.00% | -50.0% |
Q2 2020 | $632,000 | -24.8% | 13,198 | -1.1% | 0.00% | -33.3% |
Q1 2020 | $840,000 | -49.2% | 13,348 | 0.0% | 0.00% | -25.0% |
Q4 2019 | $1,654,000 | +78.4% | 13,348 | -4.4% | 0.00% | +100.0% |
Q3 2019 | $927,000 | -16.6% | 13,968 | 0.0% | 0.00% | -33.3% |
Q2 2019 | $1,111,000 | -13.5% | 13,968 | +21.7% | 0.00% | 0.0% |
Q1 2019 | $1,284,000 | +1.9% | 11,478 | -8.2% | 0.00% | -25.0% |
Q4 2018 | $1,260,000 | -20.2% | 12,498 | 0.0% | 0.00% | 0.0% |
Q3 2018 | $1,579,000 | +50.5% | 12,498 | 0.0% | 0.00% | +33.3% |
Q2 2018 | $1,049,000 | -29.8% | 12,498 | -48.5% | 0.00% | -25.0% |
Q1 2018 | $1,494,000 | +0.2% | 24,289 | -4.8% | 0.00% | 0.0% |
Q4 2017 | $1,491,000 | -2.2% | 25,522 | -2.8% | 0.00% | 0.0% |
Q3 2017 | $1,525,000 | -52.0% | 26,267 | 0.0% | 0.00% | -55.6% |
Q2 2017 | $3,180,000 | +18.5% | 26,267 | +10.7% | 0.01% | +12.5% |
Q1 2017 | $2,684,000 | +4.1% | 23,727 | -0.0% | 0.01% | 0.0% |
Q4 2016 | $2,579,000 | -32.3% | 23,736 | +2.5% | 0.01% | -33.3% |
Q3 2016 | $3,810,000 | +10.2% | 23,147 | -4.5% | 0.01% | +9.1% |
Q2 2016 | $3,456,000 | +48.3% | 24,227 | +33.6% | 0.01% | +22.2% |
Q1 2016 | $2,330,000 | -21.8% | 18,140 | -9.0% | 0.01% | -18.2% |
Q4 2015 | $2,978,000 | -14.8% | 19,940 | -5.4% | 0.01% | -21.4% |
Q3 2015 | $3,496,000 | -31.3% | 21,078 | 0.0% | 0.01% | -22.2% |
Q2 2015 | $5,088,000 | +6.0% | 21,078 | +23.9% | 0.02% | +12.5% |
Q1 2015 | $4,799,000 | +68.9% | 17,018 | -6.5% | 0.02% | +77.8% |
Q4 2014 | $2,841,000 | -34.6% | 18,209 | -0.8% | 0.01% | -35.7% |
Q3 2014 | $4,344,000 | +27.8% | 18,352 | +27.7% | 0.01% | +27.3% |
Q2 2014 | $3,399,000 | +63.3% | 14,366 | +127.6% | 0.01% | +57.1% |
Q1 2014 | $2,082,000 | +251.7% | 6,312 | -27.2% | 0.01% | +250.0% |
Q4 2013 | $592,000 | -1.2% | 8,676 | 0.0% | 0.00% | 0.0% |
Q3 2013 | $599,000 | +54.0% | 8,676 | 0.0% | 0.00% | +100.0% |
Q2 2013 | $389,000 | – | 8,676 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |